GILD Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 23.56% compared to Gilead Sciences's net margin of 50.24%. Gilead Sciences's return on equity of 2.5% beat Johnson & Johnson's return on equity of 19.98%.

Gilead Sciences has a consensus price target of $112.50, signalling upside risk potential of 7.27%. On the other hand Johnson & Johnson has an analysts' consensus of $170.21 which suggests that it could grow by 10.59%. Given that Johnson & Johnson has higher upside potential than Gilead Sciences, analysts believe Johnson & Johnson is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.322, which suggesting that the stock is 67.831% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.96%. Johnson & Johnson offers a yield of 3.22% to investors and pays a quarterly dividend of $1.24 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Gilead Sciences quarterly revenues are $7.6B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Gilead Sciences's net income of $1.8B is lower than Johnson & Johnson's net income of $11B. Notably, Gilead Sciences's price-to-earnings ratio is 283.46x while Johnson & Johnson's PE ratio is 17.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.59x versus 4.18x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 23.56% compared to Gilead Sciences's net margin of 32.59%. Gilead Sciences's return on equity of 2.5% beat Eli Lilly and's return on equity of 80.24%.

Gilead Sciences has a consensus price target of $112.50, signalling upside risk potential of 7.27%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.89 which suggests that it could grow by 37.28%. Given that Eli Lilly and has higher upside potential than Gilead Sciences, analysts believe Eli Lilly and is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.322, which suggesting that the stock is 67.831% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.96%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Gilead Sciences quarterly revenues are $7.6B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Gilead Sciences's net income of $1.8B is lower than Eli Lilly and's net income of $4.4B. Notably, Gilead Sciences's price-to-earnings ratio is 283.46x while Eli Lilly and's PE ratio is 62.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.59x versus 14.75x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 23.56% compared to Gilead Sciences's net margin of -117.16%. Gilead Sciences's return on equity of 2.5% beat Moderna's return on equity of -29.09%.

Gilead Sciences has a consensus price target of $112.50, signalling upside risk potential of 7.27%. On the other hand Moderna has an analysts' consensus of $51.14 which suggests that it could grow by 103%. Given that Moderna has higher upside potential than Gilead Sciences, analysts believe Moderna is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.322, which suggesting that the stock is 67.831% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.96%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $7.6B, which are larger than Moderna quarterly revenues of $956M. Gilead Sciences's net income of $1.8B is higher than Moderna's net income of -$1.1B. Notably, Gilead Sciences's price-to-earnings ratio is 283.46x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.59x versus 3.06x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 23.56% compared to Gilead Sciences's net margin of 31.35%. Gilead Sciences's return on equity of 2.5% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Gilead Sciences has a consensus price target of $112.50, signalling upside risk potential of 7.27%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.43 which suggests that it could grow by 2.5%. Given that Gilead Sciences has higher upside potential than Vertex Pharmaceuticals, analysts believe Gilead Sciences is more attractive than Vertex Pharmaceuticals.

Gilead Sciences has a beta of 0.322, which suggesting that the stock is 67.831% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.96%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $7.6B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.9B. Gilead Sciences's net income of $1.8B is higher than Vertex Pharmaceuticals's net income of $913M. Notably, Gilead Sciences's price-to-earnings ratio is 283.46x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.59x versus 11.44x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.